We are excited to share news from two pharmaceutical companies working on potential treatments and cures for Rett syndrome.
Taysha Gene Therapies
Taysha Gene Therapies shared that they are encouraged by the initial clinical observations of the first adult patient dosed in their TSHA-102 REVEAL Phase 1/2 gene therapy trial in Canada. Further clinical updates on the safety and efficacy observations for this first patient will arrive in Q3 2023 and the second potential patient has been identified to undergo screening. Click here to read the full release from Taysha.
IRSF is excited to continue to share updates on this trial with our Rett community. Taysha presented information on the dosing of the first gene therapy trial participant at our IRSF Rett Syndrome Scientific Meeting in Nashville on June 7th. And this potential gene therapy uses discoveries made by Dr. Steven Gray, the recipient of IRSF funding to establish his independent lab and study gene therapies to treat Rett.
Anavex Life Sciences
Anavex Life Sciences shared information on their long-term clinical study in adults with Rett syndrome of ANAVEX®2-73 (blarcamesine). Click here to read the full press release from Anavex.
We look forward to seeing the full data when published and sharing more information with our community. This compound was first tested for Rett syndrome as part of IRSF’s SCOUT program in 2017 and received additional funding from our Foundation to support early clinical trials.
Our Promise to the Rett Community
Rett is not one-size-fits-all; because Rett syndrome has a broad range of presentations, we need a broad range of treatments and cures. IRSF promises to continue to invest broadly and smartly in the most promising research to find solutions for ALL our loved ones with Rett syndrome. We are grateful to the donors who support our strategy and the families who continue to participate in clinical trials.
IRSF is with you every step of the way. We promise to continue to relentlessly pursue treatments and curative approaches to create a world without Rett syndrome. Questions? Email us at [email protected].